28.13MMarket Cap-2680P/E (TTM)
0.785High0.750Low326.35KVolume0.776Open0.795Pre Close251.37KTurnover1.09%Turnover RatioLossP/E (Static)36.18MShares5.97052wk High-11.78P/B23.27MFloat Cap0.46452wk Low--Dividend TTM29.93MShs Float12.470Historical High--Div YieldTTM4.41%Amplitude0.464Historical Low0.770Avg Price1Lot Size
BriaCell Therapeutics Stock Forum
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhib...
5 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
Interim data analysis planned at 144 eve...
No comment yet